4D Molecular Therapeutics FDMT Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's short- and long-term operating lease liabilities?
- 4D Molecular Therapeutics (FDMT) reported short- and long-term operating lease liabilities of -$878K in Q1 2026.
- How has 4D Molecular Therapeutics's short- and long-term operating lease liabilities changed year-over-year?
- 4D Molecular Therapeutics's short- and long-term operating lease liabilities decreased by 16.4% year-over-year, from -$754K to -$878K.
- What is the long-term trend for 4D Molecular Therapeutics's short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's short- and long-term operating lease liabilities has grown at a 114.4% compound annual growth rate (CAGR), from -$324K to -$3.19M.